Shares of Unum Group UNM have gained 33.6% in the past year compared with the industry's growth of 21.7%. The Finance sector has returned 4%, while the Zacks S&P 500 index has declined 1.9% in the said time frame.
Unum Group shares are trading well above the 200-day moving average, indicating a bullish trend.
The company has a market capitalization of $12.58 billion. The average volume of shares traded in the last three months was 1.53 million.
Image Source: Zacks Investment Research
UNM shares are trading at a price-to-book multiple of 1.15, lower than the industry average of 1.81. Its pricing, at a discount to the industry average, gives a better entry point to investors. Also, it has a Value Score of A. Shares of other insurers like Fidelity National Financial, Inc. AMSF and Aflac Incorporated AFL are trading at a multiple higher than the industry average, while shares of Employers Holdings Inc EIG are trading at a multiple lower than the industry average.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Unum Group’s 2025 revenues is pegged at $13.38 billion, implying a year-over-year improvement of 3.8%.
The consensus estimate for 2026 earnings per share and revenues indicates an increase of 8.6% and 4.1%, respectively, from the corresponding 2024 estimates.
Earnings have grown 12.9% in the past five years, better than the industry average of 3.6%. The accident and health insurer has a solid surprise history. It surpassed earnings estimates in three of the last four quarters and missed in one, the average beat being 2.94%.
Premiums, the primary component of UNM’s top line, continue to gain from its healthy in-force block growth and higher sales. In 2025, Unum Group expects sales growth in the range of 5-10%, premium growth in the band of 4-7% and adjusted operating return on equity (ROE) between 21% and 23% from core business. The company estimates 8-12% growth in adjusted operating EPS in 2025. For the long term, it expects sales growth in the range of 8-12%, premium growth in the band of 4-7% and adjusted operating earnings per share growth between 8% and 12%.
Unum Group is poised to grow on the operational excellence of Unum U.S. and Colonial Life. Encouraging sales trends, strong persistency in group lines and growth of new product lines like dental and vision, coupled with favorable risk results, should benefit Unum U.S. and Colonial Life, the two largest operating segments.
Management estimates sales growth of 5-10% and premium growth of 3.6%, as well as adjusted operating ROE in the range of 23-25% in 2025, for Unum U.S. It expects sales growth in the range of 5-10%, premium growth in the range of 2-4% and adjusted operating ROE in the range of 18-20% for Colonial Life in 2025.
Unum Group enjoys a solid capital position and substantial statutory earnings and capital, leading to financial flexibility.
Unum Group has consistently enhanced shareholders’ value through dividend hikes. The board has increased the shareholder dividend by 15%, effective in the third quarter of 2024, putting the dividend payout ratio right around 20%. It also marked the 15th dividend hike in the last 14 years. The dividend yield of the company was 2.3%, making it an attractive pick for yield-seeking investors.
Favorable sales trends and risk experience, strong persistency, an improving rate environment, solid capital position, higher return on capital and effective capital deployment should continue to favor UNM over the long term. The insurer should continue to gain from favorable growth estimates as well as the affordability of the stock. It is, therefore, wise to retain this Zacks Rank #3 (Hold) stock. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aflac Incorporated (AFL) : Free Stock Analysis Report
Unum Group (UNM) : Free Stock Analysis Report
AMERISAFE, Inc. (AMSF) : Free Stock Analysis Report
Employers Holdings Inc (EIG) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。